Sacituzumab tirumotecan for SMARCB1-deficient kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of advanced or metastatic renal medullary carcinoma (RMC) that has lost the SMARCB1 protein.
- Your cancer must have gotten worse after at least one prior treatment.
- You need to be well enough for daily activities (ECOG score of 0 or 1) and be 18 or older.
- You must have at least one tumor that can be measured on a scan (like CT or MRI).
- Your liver, kidney, and blood cell counts must meet certain minimum levels.
- You must agree to use effective birth control if applicable, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, sacituzumab tirumotecan, for people with anal or rectal cancer that has spread or cannot be removed and has not responded to previous treatments. The drug is designed to target and kill cancer cells.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new drug called sacituzumab tirumotecan for thymic carcinoma that has spread or come back after prior treatment. The goal is to see if this drug can help shrink or control the cancer.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
Hear when a new Phase II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.